Zacks Investment Research upgraded shares of iShares Diversified Alternatives Trust (NYSEARCA:ALT) from a hold rating to a buy rating in a report issued on Wednesday morning, Zacks.com reports. They currently have $2.50 target price on the stock.
According to Zacks, “Altimmune, Inc. is a clinical-stage immunotherapeutics company. It focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The company’s proprietary platform technologies consist of RespirVec and Densigen. Altimmune Inc., formerly known as Pharmathene Inc., is based in Gaithersburg, United States. “
Separately, Roth Capital initiated coverage on iShares Diversified Alternatives Trust in a report on Friday, July 19th. They set a buy rating and a $8.30 price objective for the company.
iShares Diversified Alternatives Trust (NYSEARCA:ALT) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.01). The business had revenue of $1.63 million during the quarter, compared to analysts’ expectations of $2.41 million.
In related news, CEO Vipin K. Garg purchased 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 5th. The stock was acquired at an average price of $2.10 per share, for a total transaction of $42,000.00. Following the completion of the acquisition, the chief executive officer now owns 342,907 shares of the company’s stock, valued at approximately $720,104.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
About iShares Diversified Alternatives Trust
iShares Diversified Alternatives Trust (the Trust) is a commodity pool. The investment objective of the Trust is to maximize absolute returns from its investments in certain futures and/or forward contracts. The Trust holds long and/or short positions in foreign currency forward contracts and exchange-traded futures contracts involving assets, such as commodities, currencies, interest rates or certain eligible stock and/or bond indices.
Featured Article: Dividend Reinvestment Plan (DRIP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for iShares Diversified Alternatives Trust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Diversified Alternatives Trust and related companies with MarketBeat.com's FREE daily email newsletter.